At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MDGL Madrigal Pharmaceuticals
Not Yet Opened 04-01 16:00:00 EDT
529.84
+6.37
+1.22%
盘后529.84
+0.000.00%
18:59 EDT
High545.26Low525.00Vol423.06K
Open531.32D1 Closing523.47Amplitude3.87%
Mkt Cap12.15BTradable Cap5.83BTotal Shares22.94M
T/O224.23MT/O Rate3.85%Tradable Shares11.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

A Look At Madrigal Pharmaceuticals (MDGL) Valuation After Recent Share Price Strength And Updated Fair Value Estimate
Simply Wall St.  ·  03-28
A Look At Madrigal Pharmaceuticals (MDGL) Valuation After Recent Share Price Strength And Updated Fair Value Estimate
Madrigal Pharmaceuticals off highs, remains up 13% in afternoon trading
TIPRANKS  ·  03-27
Madrigal Pharmaceuticals off highs, remains up 13% in afternoon trading
Analysts’ Top Healthcare Picks: Madrigal Pharmaceuticals (MDGL), IDEAYA Biosciences (IDYA)
TIPRANKS  ·  03-23
Analysts’ Top Healthcare Picks: Madrigal Pharmaceuticals (MDGL), IDEAYA Biosciences (IDYA)
Madrigal Pharmaceuticals grants 1,739 inducement RSUs under 2025 plan
Reuters  ·  03-20
Madrigal Pharmaceuticals grants 1,739 inducement RSUs under 2025 plan
Madrigal Pharmaceuticals EVP and CFO Mardi Dier Disposes of Common Shares
Reuters  ·  03-07
Madrigal Pharmaceuticals EVP and CFO Mardi Dier Disposes of Common Shares
Madrigal Pharmaceuticals grants inducement equity awards to 20 new employees
Reuters  ·  03-06
Madrigal Pharmaceuticals grants inducement equity awards to 20 new employees
Madrigal Pharmaceuticals to Participate in TD Cowen 46th Annual Health Care Conference
Reuters  ·  02-24
Madrigal Pharmaceuticals to Participate in TD Cowen 46th Annual Health Care Conference
A Look At Madrigal Pharmaceuticals (MDGL) Valuation After Rezdiffra’s First Full Year Near US$1b In Sales
Simply Wall St.  ·  02-24
A Look At Madrigal Pharmaceuticals (MDGL) Valuation After Rezdiffra’s First Full Year Near US$1b In Sales
Barclays Remains a Buy on Madrigal Pharmaceuticals (MDGL)
TIPRANKS  ·  02-22
Barclays Remains a Buy on Madrigal Pharmaceuticals (MDGL)
Madrigal Pharmaceuticals Is Maintained at Neutral by B of A Securities
Dow Jones  ·  02-20
Madrigal Pharmaceuticals Is Maintained at Neutral by B of A Securities
Madrigal Pharmaceuticals price target lowered to $529 from $570 at BofA
TIPRANKS  ·  02-20
Madrigal Pharmaceuticals price target lowered to $529 from $570 at BofA
Madrigal Pharmaceuticals: Rezdiffra’s Strong Launch, Expanding Prescriber Adoption, and Advancing Pipeline Underpin Buy Rating
TIPRANKS  ·  02-20
Madrigal Pharmaceuticals: Rezdiffra’s Strong Launch, Expanding Prescriber Adoption, and Advancing Pipeline Underpin Buy Rating
Stock Track | Madrigal Pharmaceuticals Plummets 8.75% in Pre-Market on Wider-Than-Expected Q4 Net Loss
Stock Track  ·  02-19
Stock Track | Madrigal Pharmaceuticals Plummets 8.75% in Pre-Market on Wider-Than-Expected Q4 Net Loss
BUZZ-Madrigal Pharmaceuticals down after wider-than-expected Q4 net loss
Reuters  ·  02-19
BUZZ-Madrigal Pharmaceuticals down after wider-than-expected Q4 net loss
Stock Track | Madrigal Pharmaceuticals Plunges 6.41% in Pre-Market After Q4 Earnings Miss
Stock Track  ·  02-19
Stock Track | Madrigal Pharmaceuticals Plunges 6.41% in Pre-Market After Q4 Earnings Miss
Earnings Flash (MDGL) Madrigal Pharmaceuticals Posts Q4 Net Loss $2.57 a Share, vs. FactSet Est of $0.90 Loss
MT Newswires Live  ·  02-19
Earnings Flash (MDGL) Madrigal Pharmaceuticals Posts Q4 Net Loss $2.57 a Share, vs. FactSet Est of $0.90 Loss
Madrigal posts FY 2025 net revenues of USD 958.4 million
Reuters  ·  02-19
Madrigal posts FY 2025 net revenues of USD 958.4 million
Madrigal Pharmaceuticals Q4 2025 EPS $(2.57) Misses $(0.40) Estimate, Sales $321.083M Beat $312.490M Estimate
Benzinga  ·  02-19
Madrigal Pharmaceuticals Q4 2025 EPS $(2.57) Misses $(0.40) Estimate, Sales $321.083M Beat $312.490M Estimate
BRIEF-Madrigal Pharmaceuticals Q4 EPS USD -2.57
Reuters  ·  02-19
BRIEF-Madrigal Pharmaceuticals Q4 EPS USD -2.57
Madrigal Pharmaceuticals Q4 Product Revenue USD 321.083 Million
THOMSON REUTERS  ·  02-19
Madrigal Pharmaceuticals Q4 Product Revenue USD 321.083 Million

Introduction

Company Name.
Madrigal Pharmaceuticals
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor beta agonist, which is in Phase III clinical trials for treating NASH. The company is also developing MGL-3745, a backup compound to resmetirom. The company is headquartered in West Conshohocken, Pennsylvania.
Issue price:
--